Stock·NYSE·Healthcare
ResMed Inc. (RMD)
- Market cap
- $32.24B
- P/E
- 21.98
- Dividend yield
- 1.07%
- Street target
- $240.00median of 20 analysts
- 52-week range
- $180.27 $277.67
RMD stock forecast today
Where RMD stands today, and what CleaRank Financial AI makes of it.
RMD at a glance
ResMed Inc. (RMD): Buy, 67/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($224.88 and $231.78).
- Earnings RMD beat estimates in 6 of the 6 reports in our data, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $40.9M and made no open-market purchases over the last 18 months.
- Valuation P/E of 22.0 against 31.9 for the Healthcare sector: a discount to peers (-31%).
Figures as of October 30, 2026.
CleaRank Financial AI
ResMed Inc. (RMD) earns a CleaRank rating of Buy with a model score of 67/100.
Profitability does the most to lift that score: a net margin of 26.95%, return on equity of 24.27% above the sector median, and debt-to-equity of 0.13. Trend is mixed, with the stock 1.09% below its 50-day average of $231.78 yet 1.95% above its 200-day average of $224.88. Over the past year, the price declined 9.12%.
Only on CleaRank
Figures we compute ourselves from RMD's own price, earnings and insider-filing history. Tap one to see it in context.
RMD stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price below its 50-day average ›
The price of $229.26 is 1.1% below the 50-day simple moving average of $231.78.Price above its 200-day average ›
The price is 1.9% above the 200-day simple moving average of $224.88.50-day average above the 200-day ›
The 50-day average ($231.78) is 3.1% above the 200-day average ($224.88), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 50% of its 52-week range, between $180.27 and $277.67.
RMD share price
Pick a period: each tab shows how far RMD has moved over it, to the last close.
Today's trading
Where RMD sits inside today's range and its 52-week range.
RMD fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/5P/E below the sector median ›
The trailing P/E of 21.98 is 31.1% below the Healthcare median of 31.9.P/S above the sector median ›
The price-to-sales ratio of 5.70 is 67.7% above the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $1.5B on revenue of $5.7B, a net margin of 26.9%.Beat estimates in most recent reports ›
RMD beat the EPS estimate in 6 of the 6 reports in our data.Pays a dividend ›
The trailing dividend yield is 1.07%, or $2.46 a share a year.
Key statistics
The headline figures for RMD.
As of October 30, 2026, RMD trades at $229.26, with a market value of $32.24B, a P/E ratio of 21.98 and a dividend yield of 1.07%.
What the numbers say
CleaRank Financial AI's reading of RMD's valuation, growth and risks.
ResMed Inc. (RMD) trades at a P/E of 21.98, which is 31.1% below the Healthcare sector median P/E of 31.9; that gap is what makes its valuation a discount to peers. Measured on sales, the P/S of 5.70 sits 67.6% above the sector median of 3.4. To put the size in context, the company has a market value of $32.2B and trailing earnings of $10.43 per share.
Margins stand at a net margin of 26.95% and an operating margin of 30.86%. It generates a return on equity of 24.27%, above the sector median of 7.3%. Debt-to-equity of 0.13 and a trailing dividend yield of 1.07% ($2.46 a share a year) round out the fundamentals.
ResMed Inc. (RMD) beat its EPS estimate by 2.08% in the August 6, 2026 report, posting $2.95 against an expected $2.89. The share price nonetheless dropped 5.06% in the first session after the report.
RMD has beaten the EPS estimate in all 6 reports in our data; even so, 3 of those 6 beats were followed by a lower share price the next session. Looking ahead, analysts expect EPS of $12.09 this fiscal year (growth of 8.3%) and $13.26 the year after (growth of 9.6%).
RMD's daily returns have a 30-day standard deviation of 2.13%, and its beta against the S&P 500 is 0.75. The stock is 17.43% below its 52-week high of $277.67. Insider sales over the last 18 months added up to $40.9M, with no open-market purchases. Insider sales are often planned in advance or made to cover taxes on vesting shares, so they carry less weight than open-market buying.
RMD against the Healthcare sector
How RMD compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: RMD trades at a notable discount to sector peers (-31%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 20, 2025, RMD has lost 7.6% against a gain of 37.3% for XLV.
Performance against XLV
RMD and the Healthcare sector fund over the same days.
Revenue and earnings
How much RMD sells, and how much of it becomes profit.
The quarterly bars end with Q1 '26 (the quarter to March 31, 2026); RMD reported again on August 6, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 9.8% in FY2025 to $5.1B, from $4.7B a year earlier.
Profit margin: The net margin was 27.2% in FY2025, up from 21.8% the year before.
Profitable: RMD earned $1.4B in FY2025.
Earnings reality check
Did RMD beat what analysts expected, and how did the stock react?
Earnings record: RMD beat the analyst estimate in 6 of the 6 reports in our data.
Market reaction: The stock fell in the first session after 3 of those 6 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Aug 6, 2026after close | $2.89 | $2.95 | +2.08% | -5.06% | +1.57% |
| Apr 30, 2026after close | $2.80 | $2.86 | +2.14% | -4.11% | -3.24% |
| Jan 29, 2026after close | $2.72 | $2.81 | +3.31% | +0.27% | +3.66% |
| Jul 31, 2025after close | $2.48 | $2.55 | +2.82% | +2.67% | +3.03% |
| Apr 23, 2025after close | $2.36 | $2.37 | +0.42% | +10.10% | +10.33% |
| Jan 30, 2025after close | $2.31 | $2.43 | +5.19% | -8.33% | -7.94% |
As of October 30, 2026, RMD has beaten the analyst EPS estimate in 6 of the 6 reports in our data and fell in the first trading session after 3 of those beats; its latest report, on August 6, 2026, came in 2.08% above the estimate and the stock moved -5.06% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
RMD AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 41.2, in neutral territory.RSI below 50 ›
An RSI of 41.2 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of RMD
The score, the reasoning behind it, and what could move the price next.
ResMed Inc. (RMD) is caught between its two moving averages. At $229.26, the stock stands 1.95% above its 200-day average of $224.88 but 1.09% below its 50-day average of $231.78. That 50-day average is 3.07% above the 200-day one. Across the 52-week range from $180.27 to $277.67, today's price sits at 50% of the distance.
Recent gains sit on top of a weaker longer record. Over the past month the price rose 3.69% and over the past three months it rose 8.66%, but over the past year it fell 9.12%. The last session saw the price fall 9.32% on trading volume that ran 280.1% above its average. The 14-day RSI reads 41.2, which is neutral, and the MACD line is positive.
Analyst upgrade ›
RBC Capital upgraded it to Outperform from Sector Perform on September 15, 2026.
Source: Analyst action, RBC Capital, September 15, 2026
Earnings beat, but the stock fell ›
The August 6, 2026 report beat the EPS estimate by 2.08%, and the share price fell 5.06% in the first session after it.
Source: Earnings report, August 6, 2026New analyst coverage ›
Rothschild & Co started coverage at Neutral on August 19, 2026.
Source: Analyst action, Rothschild & Co, August 19, 2026
- Two levels deserve the closest watch: the 50-day SMA at $231.78, which sits above the price, and the 200-day SMA at $224.88, which sits below it.
- ResMed Inc. (RMD) shows a 14-day RSI of 41.2, which is neutral, and the MACD line is positive. Readings above 70 or below 30 would point to stretched momentum.
- The share price dropped 5.06% in the first session after the August 6, 2026 report. Even so, RMD has beaten estimates in 6 of the 6 reports in our data.
RMD sits above its 200-day average of $224.88 but below its 50-day average of $231.78, so the trend is mixed. Should the price close above the 50-day, both signals would point up. A close below the 200-day would point both down. For now the price is wedged between the 200-day SMA ($224.88) beneath it and the 50-day SMA ($231.78) above it.
ResMed Inc. (RMD) has a 14-day RSI of 41.2, which places it in the neutral zone between 40 and 60.
Technical indicators
Momentum and trend for RMD, from its daily closes.
As of October 30, 2026, with RMD at $229.26, its 14-day RSI is 41.2 (neutral territory), its 50-day simple moving average is $231.78 and its 200-day is $224.88.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What RMD moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, RMD's 1-year correlation of daily returns is +0.33 with S&P 500 (SPY), +0.22 with Nasdaq 100 (QQQ), +0.06 with Bitcoin (BTC) and +0.14 with gold (XAU).
RMD price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Fewer than half of analysts rate it a buy ›
9 of 20 analysts rate it a buy or strong buy, 10 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $240.00 is 4.7% above the price.More buy ratings than three months ago ›
9 of 20 rate it a buy now, against 7 of 18 three months ago.
RMD Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 15, 2026 | RBC Capital | Upgrade | Outperform |
| Aug 31, 2026 | Keybanc | Maintains | Overweight |
| Aug 19, 2026 | Rothschild & Co | Initiates | Neutral |
| Aug 7, 2026 | RBC Capital | Maintains | Sector Perform |
| Aug 7, 2026 | Piper Sandler | Maintains | Neutral |
| Aug 7, 2026 | Keybanc | Maintains | Overweight |
As of October 30, 2026, 20 Wall Street analysts cover RMD: 9 rate it a buy or strong buy, 10 a hold and 1 a sell or strong sell. Their 12-month price targets range from $175.00 to $320.00. The median RMD price target is $240.00, 4.7% above the price of $229.26.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
RMD trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
RMD trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from RMD's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much RMD tends to move, against the market and on its own.
RMD price history and drawdowns
RMD's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
3/4Average daily move of 2% or more ›
The price has moved 2.13% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 52.8%, from September 2021 to October 2023, regained by August 2025.Most 1-year holds ended higher ›
73% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $47,238, against $42,358 in the S&P 500 (SPY).
RMD Drawdowns & Recovery
As of October 30, 2026, RMD's worst peak-to-trough fall over the last 10 years with dividends reinvested was -52.8% (September 2021 to October 2023); it regained that peak by August 2025, 22 months after the low, and 73% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into RMD in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: RMD beat the S&P 500 over this period: $47,238 against $42,358.
A $10,000 investment in RMD in October 2016 would be worth about $47,238 today with dividends reinvested, compared with about $42,358 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to RMD, and which have not.
Strongest month, June: an average of +6.03%, up in 8 of 10 years.
Weakest month, September: an average of -4.19%, up in 1 of 10 years.
This month, October: has averaged +1.14%, up in 6 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, RMD's strongest calendar month has been June (average +6.03%, up in 8 of 10 years) and its weakest September (average -4.19%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
RMD stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in RMD, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in RMD today could grow to about $14,302 by 2030 in the base case, with a 90th-percentile outcome near $32,519 and a 10th-percentile outcome around $6,290. The simulation models price only; at today's 1.07% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
RMD Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $328 for RMD by 2030 in the base case, from $229 today (1.4x over 4 years). The 10th-percentile path ends near $144. These are outcomes of a Monte Carlo simulation run on RMD's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $166 | $251 | $378 | |
| 2028 | $153 | $274 | $490 | |
| 2029 | $147 | $300 | $611 | |
| 2030 | $144 | $328 | $746 |
Method: a lognormal simulation of RMD's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
RMD insider trading
What the people running the company have bought and sold.
RMD insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: No insider bought RMD shares on the open market in the last 18 months. Sales are often planned in advance or cover tax on vesting shares, so they say less than purchases would.
As of October 30, 2026, RMD insiders reported 51 open-market sales worth $40.9M and no open-market purchases over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 23, 2026 | Michael J Rider
Officer
|
Sell | 400 | $102.0K |
| Oct 7, 2026 | Michael J. Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.1M |
| Oct 7, 2026 | Michael J. Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Sep 8, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.1M |
| Sep 8, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Aug 14, 2026 | Aaron Bloomer
Chief Financial Officer
|
Grant | 9.1K | - |
| Aug 14, 2026 | Justin Leong
Officer
|
Grant | 6.5K | - |
| Aug 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.0M |
| Aug 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Aug 5, 2026 | Peter Craig Farrell
Director
|
Sell | 8.0K | $1.8M |
| Jun 8, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $968.1K |
| Jun 8, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| May 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.0M |
| May 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Apr 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.1M |
| Apr 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Apr 1, 2026 | Peter Craig Farrell
Director
|
Sell | 2.0K | $450.0K |
| Apr 1, 2026 | Brett Sandercock
Chief Financial Officer
|
Sell | 1.0K | $224.3K |
| Mar 9, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.3M |
| Mar 9, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Mar 4, 2026 | Peter Craig Farrell
Director
|
Sell | 2.0K | $520.4K |
| Mar 2, 2026 | Brett Sandercock
Chief Financial Officer
|
Sell | 1.0K | $254.3K |
| Feb 9, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.4M |
| Feb 9, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Feb 4, 2026 | Peter Craig Farrell
Director
|
Sell | 2.0K | $502.6K |
| Feb 4, 2026 | Michael J Rider
General Counsel
|
Sell | 50 | $13.0K |
| Feb 2, 2026 | Brett Sandercock
Chief Financial Officer
|
Sell | 1.0K | $257.0K |
| Jan 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.2M |
| Jan 7, 2026 | Peter Craig Farrell
Director
|
Sell | 2.0K | $497.7K |
| Jan 7, 2026 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Jan 2, 2026 | Brett Sandercock
Chief Financial Officer
|
Sell | 1.0K | $241.8K |
| Jan 2, 2026 | Michael J Rider
Officer
|
Sell | 50 | $12.1K |
| Dec 8, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 5.0K | $1.3M |
| Dec 8, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 5.0K | $730.4K |
| Dec 3, 2025 | Peter Craig Farrell
Director
|
Sell | 2.0K | $502.9K |
| Dec 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 1.0K | $244.2K |
| Dec 1, 2025 | Michael J Rider
Officer
|
Sell | 50 | $12.2K |
| Nov 25, 2025 | Witte Jan De
Director
|
Sell | 2.1K | $524.0K |
| Nov 20, 2025 | Carol J Burt
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | Christopher Delorefice
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | Witte Jan De
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | Karen Drexler
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | Michael J Farrell
Chief Executive Officer
|
Grant | 13.6K | - |
| Nov 20, 2025 | Peter Craig Farrell
Director
|
Grant | 536 | - |
| Nov 20, 2025 | Harjit Gill
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | John Hernandez
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | Justin Leong
Officer
|
Grant | 1.8K | - |
| Nov 20, 2025 | Nicole Mowad-Nassa
Director
|
Grant | 536 | - |
| Nov 20, 2025 | Brett Sandercock
Chief Financial Officer
|
Grant | 2.7K | - |
| Nov 20, 2025 | Desney Tan
Director
|
Grant | 1.1K | - |
| Nov 20, 2025 | Ronald R Taylor
Director
|
Grant | 1.1K | - |
| Nov 14, 2025 | Peter Craig Farrell
Director
|
Option | 11.4K | $1.2M |
| Nov 12, 2025 | Peter Craig Farrell
Director
|
Sell | 2.0K | $504.1K |
| Nov 11, 2025 | Witte Jan De
Director
|
Sell | 487 | $121.9K |
| Nov 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 8.0K | $2.0M |
| Nov 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 8.0K | $814.2K |
| Nov 3, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 3.0K | $742.6K |
| Nov 3, 2025 | Brett Sandercock
Chief Financial Officer
|
Option | 2.0K | $203.3K |
| Oct 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 8.0K | $2.3M |
| Oct 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 8.0K | $814.0K |
| Oct 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 3.0K | $823.1K |
| Oct 1, 2025 | Michael J Rider
Officer
|
Sell | 100 | $27.4K |
| Oct 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Option | 2.0K | $203.3K |
| Sep 8, 2025 | Michael J. Farrell
Chief Executive Officer
|
Sell | 8.0K | $2.2M |
| Sep 8, 2025 | Michael J. Farrell
Chief Executive Officer
|
Option | 8.0K | $814.0K |
| Sep 2, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 3.0K | $812.3K |
| Sep 2, 2025 | Nicole Mowad-Nassa
Director
|
Grant | 241 | - |
| Sep 2, 2025 | Brett Sandercock
Chief Financial Officer
|
Option | 2.0K | $203.3K |
| Aug 18, 2025 | John Hernandez
Director
|
Sell | 2.6K | $739.3K |
| Aug 18, 2025 | John Hernandez
Director
|
Option | 2.6K | $383.4K |
| Aug 15, 2025 | Michael J Farrell
Chief Executive Officer
|
Grant | 12.3K | - |
| Aug 15, 2025 | Justin Leong
Officer
|
Grant | 5.5K | - |
| Aug 15, 2025 | Michael J Rider
Officer
|
Grant | 2.9K | - |
| Aug 15, 2025 | Brett Sandercock
Chief Financial Officer
|
Grant | 5.5K | - |
| Aug 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 8.0K | $2.2M |
| Aug 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 8.0K | $814.0K |
| Aug 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 3.0K | $845.7K |
| Aug 1, 2025 | Michael J Rider
General Counsel
|
Sell | 50 | $14.1K |
| Aug 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Option | 2.0K | $203.3K |
| Jul 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 8.0K | $2.1M |
| Jul 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 8.0K | $814.0K |
| Jul 2, 2025 | Peter Craig Farrell
Director
|
Sell | 945 | $241.4K |
| Jul 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 3.9K | $997.9K |
| Jul 1, 2025 | Michael J Rider
General Counsel
|
Sell | 66 | $17.0K |
| Jul 1, 2025 | Brett Sandercock
Chief Financial Officer
|
Option | 2.9K | $293.0K |
| Jun 9, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 8.0K | $2.0M |
| Jun 9, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 8.0K | $814.0K |
| Jun 4, 2025 | Peter Craig Farrell
Director
|
Sell | 2.0K | $494.6K |
| Jun 2, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 1.0K | $243.8K |
| Jun 2, 2025 | Michael J Rider
Officer
|
Sell | 41 | $10.0K |
| May 22, 2025 | Brett Sandercock
Chief Financial Officer
|
Sell | 3.6K | $891.3K |
| May 20, 2025 | Witte Jan De
Director
|
Sell | 2.0K | $486.9K |
| May 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Sell | 8.0K | $1.9M |
| May 7, 2025 | Peter Craig Farrell
Director
|
Sell | 2.0K | $484.5K |
| May 7, 2025 | Michael J Farrell
Chief Executive Officer
|
Option | 8.0K | $814.0K |
Source: TwelveData, from SEC Form 4 filings
RMD stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.